Skip to main content
Fig. 8 | Breast Cancer Research

Fig. 8

From: Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins

Fig. 8

Mammary tumor cells respond to select targeted treatments. Black curves indicate potency in the B1/P/Rbf cell line and blue curves potency in the B1/P cell line. Cells display sensitivity to chemotherapeutic agents, PI3K/mTOR dual inhibition, and MEK inhibition, and are resistant to CDK4/6 and EGFR/Her2 inhibition. A Topoisomerase I inhibitor, irinotecan/SN38. B Topoisomerase II inhibitor, doxorubicin. C Microtubule inhibitor, paclitaxel. D CDK4/6 inhibitor, palbociclib. E–F) EGFR/Her2 inhibitors, afatinib and neratinib. G-H PI3K/mTOR inhibitors, BEZ235 and gedatolisib. I–J) PI3K inhibitors, alpelisib and buparlisib. K mTOR inhibitor, rapamycin. L MEK inhibitor, trametinib. Differences between EC50 values were evaluated by extra sum-of-squares F test using Graph Pad Prism. M Western blot analysis shows activation of PI3K pathway by increased phosphorylation of AKT and S6 in mammary tumors of P/Rbf and B1/P/Rbf tumors compared to normal mammary gland, N Inhibition of PI3K and MEK pathways after 4 h of treatment with BEZ235 or Trametinib in B1/P/Rbf cell line. C = control (DMSO-treated cells), B = BEZ235 (200 nM) treated cells, T = trametinib (200 nM) treated cells

Back to article page